Presentation is loading. Please wait.

Presentation is loading. Please wait.

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer  Soyeon Kim, PhD, Tae Min Kim, MD, PhD,

Published byTron Løken Modified over 5 years ago

Similar presentations

Presentation on theme: "Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer  Soyeon Kim, PhD, Tae Min Kim, MD, PhD,"— Presentation transcript:

1 Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer  Soyeon Kim, PhD, Tae Min Kim, MD, PhD, Dong-Wan Kim, MD, PhD, Heounjeong Go, MD, Bhumsuk Keam, MD, Se-Hoon Lee, MD, PhD, Ja-Lok Ku, PhD, Doo Hyun Chung, MD, PhD, Dae Seog Heo, MD, PhD  Journal of Thoracic Oncology  Volume 8, Issue 4, Pages (April 2013) DOI: /JTO.0b013e318283dcc0 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 ALK fusion transcripts and ALK mutations. (A) Virtual gel electro-phoresis was performed on multiple RT-PCR products derived from patients’ specimens (n = 7) and NSCLC cells (n = 3). The suffix “B” indicates tumor specimens before crizotinib treatment. Four and two patients harbored EML4-ALK variants 1 and 3, respectively. The KIF5B-ALK fusion transcript was detected in an SNU7 patient. (B) Electropherograms showed the 4713 G→C and 4493 C→A mutations in an SNU1 patient. (C) L1196M and G1269A were detected by mutation-specific PCR assays. ALK, anaplastic lymphoma kinase; NSCLC, non–small-cell lung cancer; RT-PCR, reverse transcription–polymerase chain reaction. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318283dcc0) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 L1196M and G1269A mutant clones are resistant to crizotinib treatment. (A) 293T cells transiently transfected with EML4-ALK WT, L1196M, and G1269A constructs showed ineffective suppression of phospho-ALK in crizotinib-resistant clones. (B) Ba/F3 cells were transformed to express wild-type EML4-ALK or EML4-ALK harboring L1196M or G1269A mutations. The parental Ba/F3 cells with IL-3 or the EML4-ALK-expressing Ba/F3 cells without IL-3 were treated with crizotinib. Cell cytotoxicity was measured using CCK-8. The IC50 values were , 0.049, 0.216, and µM in Ba/F3+IL3, Ba/F3-WT, Ba/F3-L1196M, and Ba/F3-G1269A cells, respectively. ALK, anaplastic lymphoma kinase; IL, interleukin. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318283dcc0) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 ALK mutant NSCLC cells are resistant to crizotinib treatment. (A) A cell viability assay was plotted for H3122, SNU-2535, and H3122 CR1 cells (crizotinib-resistant) treated with or without crizotinib for 72 hours. (B) Phospho-ALK downstream signals were less suppressed after treatment with crizotinib in SNU-2535 and H3122 CR1 cells than in H3122 cells. (C) Apoptosis induction was high in H3122 cells compared with that in SNU-2535 cells treated with crizotinib. ALK, anaplastic lymphoma kinase; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318283dcc0) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Heterogeneous genetic alterations in patients with acquired crizotinib resistance. (A) The SNU5 patient had an average ALK copy number gain of 8.5 in the post-crizotinib specimen compared with 2.0 in the pre-crizotinib specimen. (B) EGFR high polysomy was observed in the SNU5 patient in the post-crizotinib sample. (C) Amphiregulin and (D) EGF concentrations in patients and NSCLC cells. NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318283dcc0) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer  Soyeon Kim, PhD, Tae Min Kim, MD, PhD,"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
WT1 Promotes Invasion of NSCLC via Suppression of CDH1

WT1 Promotes Invasion of NSCLC via Suppression of CDH1
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
Rafal Dziadziuszko, MD, PhD, Anh T

Rafal Dziadziuszko, MD, PhD, Anh T
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,
Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene  Madoka Kimura,

Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene  Madoka Kimura,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer  Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.

Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer  Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.
Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative.

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative.

Similar presentations

Ads by Google